



Zelda Therapeutics Ltd  
ACN 103 782 378  
[www.zeldatherapeutics.com](http://www.zeldatherapeutics.com)  
Level 4  
216 St Georges Terrace,  
Perth Western Australia 6000

By Email: dale.allen@asx.com.au

17 November 2016

Mr Dale Allen  
Senior Advisor, Listings Perth  
ASX Compliance Pty Limited  
Level 40, Central Park  
152-158 St Georges Terrace  
Perth, WA

Dear Sir

**Confirmation statement: Zelda Therapeutics Limited**

Zelda Therapeutics Limited (formerly Gleneagle Gold Limited) (**Company**) confirms the following:

1. That the conditions to the public offer under the Company's prospectus dated 11 July 2016, supplementary prospectus dated 11 October 2016 and second supplementary prospectus dated 7 November 2016 (**Prospectus**) have been satisfied. On 17 November 2016, the Company issued 160 million fully paid ordinary shares in the Company (**Shares**) pursuant to the Prospectus.
2. The conditions precedent under the Share Sale Agreements between the Company, Zelda Therapeutics Pty Limited (ACN 607 538 876) (**Zelda**) and the shareholders in that company have been satisfied with completion occurring on 17 November 2016, including the issue of 320 million Shares.
3. On 17 November 2016, the Company issued:
  - (a) 52.5 million Shares to the Zelda convertible noteholders;
  - (b) 16 million Shares to CPS Capital Pty Limited; and
  - (c) 40 million options to former and current employees and to Merchant Funds Management Pty Limited.
4. There are no, legal, regulatory or contractual impediments to the Company undertaking the activities the subject of the commitments disclosed in the Prospectus, and in particular the directors have obtained advice in respect of the proposed operations in Spain, Australia and Canada and are confident that there is no legal impediment, with reference to (as applicable) Spanish law, Australian law and Canadian law, to the Company carrying out its proposed operations.
5. An updated pro forma balance sheet based on funds raised under the Prospectus was provided to ASX on 17 November 2016.
6. There have been no material subsequent events to alter the Company's consolidated statement of financial position as detailed in section 6 of the Prospectus.
7. The consultancy fee payable in accordance with the Biologic Consultancy Agreement (as set out in section 8.7 of the Prospectus) is \$10,000 (plus GST) per month.
8. The Company is in compliance with the listing rules and in particular listing rule 3.1.

Yours faithfully

Neville Bassett  
Company Secretary